Photodynamic therapy for chronic central serous chorioretinopathy

José M. Ruiz-Moreno, Francisco L. Lugo, Felix Armadá, Rufino Silva, Javier A. Montero, J Fernando Arevalo, Luis Arias, Francisco Gómez-Ulla

Research output: Contribution to journalArticle

Abstract

Purpose: This study aimed to evaluate the efficacy of photodynamic therapy (PDT) in treating chronic central serous chorioretinopathy (CSC). Methods: We describe a non-randomized, multicentre, interventional case series. A total of 82 eyes of 72 patients with chronic CSC were treated by conventional PDT. LogMAR best corrected visual acuity (BCVA) (ETDRS charts) and central foveal thickness (CFT) measured by optical coherence tomography before and after PDT, number of PDT treatments and complications were used as outcome indicators. Results: Mean follow-up was 12 ± 10 months and mean age was 46 ± 10 years. Mean logMAR BCVA changed from 0.53 (standard deviation [SD] 0.43) before PDT to 0.38 (SD 0.41) at 3 months and 0.48 (SD 0.50) at 6 months (p <0.0001 and p = 0.007, respectively, Student's t-test for paired data). Mean BCVA at the end of follow-up was 0.37 (SD 0.45; p <0.0001 from baseline). Macular detachment was resolved and subretinal fluid (SRF) disappeared in all cases. Central foveal thickness decreased from 325 μm (SD 95), to 229 μm (SD 70) at 1 month after PDT, 206 μm (SD 68) at 3 months, and 202 μm (SD 76) at 6 months (all p <0.0001, Student's t-test for paired data). No cases developed severe visual loss or complications derived from PDT. Reactive retinal pigment epithelium hypertrophy appeared in nine cases after PDT. Conclusions: Photodynamic therapy with verteporfin may be useful in chronic CSC for improving BCVA and reducing SRF and CFT. Randomized studies with longer follow-up are needed to assess the real role of this treatment in chronic CSC.

Original languageEnglish (US)
Pages (from-to)371-376
Number of pages6
JournalActa Ophthalmologica
Volume88
Issue number3
DOIs
StatePublished - May 2010
Externally publishedYes

Fingerprint

Central Serous Chorioretinopathy
Photochemotherapy
Visual Acuity
Subretinal Fluid
Students
Retinal Pigment Epithelium
Optical Coherence Tomography
Hypertrophy

Keywords

  • Central serous chorioretinopathy
  • Optical coherence tomography
  • Photodynamic therapy
  • Retinal pigment epithelium

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Ruiz-Moreno, J. M., Lugo, F. L., Armadá, F., Silva, R., Montero, J. A., Arevalo, J. F., ... Gómez-Ulla, F. (2010). Photodynamic therapy for chronic central serous chorioretinopathy. Acta Ophthalmologica, 88(3), 371-376. https://doi.org/10.1111/j.1755-3768.2008.01408.x

Photodynamic therapy for chronic central serous chorioretinopathy. / Ruiz-Moreno, José M.; Lugo, Francisco L.; Armadá, Felix; Silva, Rufino; Montero, Javier A.; Arevalo, J Fernando; Arias, Luis; Gómez-Ulla, Francisco.

In: Acta Ophthalmologica, Vol. 88, No. 3, 05.2010, p. 371-376.

Research output: Contribution to journalArticle

Ruiz-Moreno, JM, Lugo, FL, Armadá, F, Silva, R, Montero, JA, Arevalo, JF, Arias, L & Gómez-Ulla, F 2010, 'Photodynamic therapy for chronic central serous chorioretinopathy', Acta Ophthalmologica, vol. 88, no. 3, pp. 371-376. https://doi.org/10.1111/j.1755-3768.2008.01408.x
Ruiz-Moreno, José M. ; Lugo, Francisco L. ; Armadá, Felix ; Silva, Rufino ; Montero, Javier A. ; Arevalo, J Fernando ; Arias, Luis ; Gómez-Ulla, Francisco. / Photodynamic therapy for chronic central serous chorioretinopathy. In: Acta Ophthalmologica. 2010 ; Vol. 88, No. 3. pp. 371-376.
@article{e09eeb74836146359871893c01f19d8e,
title = "Photodynamic therapy for chronic central serous chorioretinopathy",
abstract = "Purpose: This study aimed to evaluate the efficacy of photodynamic therapy (PDT) in treating chronic central serous chorioretinopathy (CSC). Methods: We describe a non-randomized, multicentre, interventional case series. A total of 82 eyes of 72 patients with chronic CSC were treated by conventional PDT. LogMAR best corrected visual acuity (BCVA) (ETDRS charts) and central foveal thickness (CFT) measured by optical coherence tomography before and after PDT, number of PDT treatments and complications were used as outcome indicators. Results: Mean follow-up was 12 ± 10 months and mean age was 46 ± 10 years. Mean logMAR BCVA changed from 0.53 (standard deviation [SD] 0.43) before PDT to 0.38 (SD 0.41) at 3 months and 0.48 (SD 0.50) at 6 months (p <0.0001 and p = 0.007, respectively, Student's t-test for paired data). Mean BCVA at the end of follow-up was 0.37 (SD 0.45; p <0.0001 from baseline). Macular detachment was resolved and subretinal fluid (SRF) disappeared in all cases. Central foveal thickness decreased from 325 μm (SD 95), to 229 μm (SD 70) at 1 month after PDT, 206 μm (SD 68) at 3 months, and 202 μm (SD 76) at 6 months (all p <0.0001, Student's t-test for paired data). No cases developed severe visual loss or complications derived from PDT. Reactive retinal pigment epithelium hypertrophy appeared in nine cases after PDT. Conclusions: Photodynamic therapy with verteporfin may be useful in chronic CSC for improving BCVA and reducing SRF and CFT. Randomized studies with longer follow-up are needed to assess the real role of this treatment in chronic CSC.",
keywords = "Central serous chorioretinopathy, Optical coherence tomography, Photodynamic therapy, Retinal pigment epithelium",
author = "Ruiz-Moreno, {Jos{\'e} M.} and Lugo, {Francisco L.} and Felix Armad{\'a} and Rufino Silva and Montero, {Javier A.} and Arevalo, {J Fernando} and Luis Arias and Francisco G{\'o}mez-Ulla",
year = "2010",
month = "5",
doi = "10.1111/j.1755-3768.2008.01408.x",
language = "English (US)",
volume = "88",
pages = "371--376",
journal = "Acta Ophthalmologica",
issn = "0001-639X",
publisher = "Copenhagen Scriptor",
number = "3",

}

TY - JOUR

T1 - Photodynamic therapy for chronic central serous chorioretinopathy

AU - Ruiz-Moreno, José M.

AU - Lugo, Francisco L.

AU - Armadá, Felix

AU - Silva, Rufino

AU - Montero, Javier A.

AU - Arevalo, J Fernando

AU - Arias, Luis

AU - Gómez-Ulla, Francisco

PY - 2010/5

Y1 - 2010/5

N2 - Purpose: This study aimed to evaluate the efficacy of photodynamic therapy (PDT) in treating chronic central serous chorioretinopathy (CSC). Methods: We describe a non-randomized, multicentre, interventional case series. A total of 82 eyes of 72 patients with chronic CSC were treated by conventional PDT. LogMAR best corrected visual acuity (BCVA) (ETDRS charts) and central foveal thickness (CFT) measured by optical coherence tomography before and after PDT, number of PDT treatments and complications were used as outcome indicators. Results: Mean follow-up was 12 ± 10 months and mean age was 46 ± 10 years. Mean logMAR BCVA changed from 0.53 (standard deviation [SD] 0.43) before PDT to 0.38 (SD 0.41) at 3 months and 0.48 (SD 0.50) at 6 months (p <0.0001 and p = 0.007, respectively, Student's t-test for paired data). Mean BCVA at the end of follow-up was 0.37 (SD 0.45; p <0.0001 from baseline). Macular detachment was resolved and subretinal fluid (SRF) disappeared in all cases. Central foveal thickness decreased from 325 μm (SD 95), to 229 μm (SD 70) at 1 month after PDT, 206 μm (SD 68) at 3 months, and 202 μm (SD 76) at 6 months (all p <0.0001, Student's t-test for paired data). No cases developed severe visual loss or complications derived from PDT. Reactive retinal pigment epithelium hypertrophy appeared in nine cases after PDT. Conclusions: Photodynamic therapy with verteporfin may be useful in chronic CSC for improving BCVA and reducing SRF and CFT. Randomized studies with longer follow-up are needed to assess the real role of this treatment in chronic CSC.

AB - Purpose: This study aimed to evaluate the efficacy of photodynamic therapy (PDT) in treating chronic central serous chorioretinopathy (CSC). Methods: We describe a non-randomized, multicentre, interventional case series. A total of 82 eyes of 72 patients with chronic CSC were treated by conventional PDT. LogMAR best corrected visual acuity (BCVA) (ETDRS charts) and central foveal thickness (CFT) measured by optical coherence tomography before and after PDT, number of PDT treatments and complications were used as outcome indicators. Results: Mean follow-up was 12 ± 10 months and mean age was 46 ± 10 years. Mean logMAR BCVA changed from 0.53 (standard deviation [SD] 0.43) before PDT to 0.38 (SD 0.41) at 3 months and 0.48 (SD 0.50) at 6 months (p <0.0001 and p = 0.007, respectively, Student's t-test for paired data). Mean BCVA at the end of follow-up was 0.37 (SD 0.45; p <0.0001 from baseline). Macular detachment was resolved and subretinal fluid (SRF) disappeared in all cases. Central foveal thickness decreased from 325 μm (SD 95), to 229 μm (SD 70) at 1 month after PDT, 206 μm (SD 68) at 3 months, and 202 μm (SD 76) at 6 months (all p <0.0001, Student's t-test for paired data). No cases developed severe visual loss or complications derived from PDT. Reactive retinal pigment epithelium hypertrophy appeared in nine cases after PDT. Conclusions: Photodynamic therapy with verteporfin may be useful in chronic CSC for improving BCVA and reducing SRF and CFT. Randomized studies with longer follow-up are needed to assess the real role of this treatment in chronic CSC.

KW - Central serous chorioretinopathy

KW - Optical coherence tomography

KW - Photodynamic therapy

KW - Retinal pigment epithelium

UR - http://www.scopus.com/inward/record.url?scp=77951722846&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951722846&partnerID=8YFLogxK

U2 - 10.1111/j.1755-3768.2008.01408.x

DO - 10.1111/j.1755-3768.2008.01408.x

M3 - Article

C2 - 19958296

AN - SCOPUS:77951722846

VL - 88

SP - 371

EP - 376

JO - Acta Ophthalmologica

JF - Acta Ophthalmologica

SN - 0001-639X

IS - 3

ER -